These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38631259)

  • 1. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
    Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
    Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma.
    Atwa SM; Handoussa H; Hosny KM; Odenthal M; El Tayebi HM
    World J Hepatol; 2020 Dec; 12(12):1211-1227. PubMed ID: 33442449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
    Mekky RY; Ragab MF; Manie T; Attia AA; Youness RA
    Transl Oncol; 2023 May; 31():101653. PubMed ID: 36907052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
    Xu Y; Cui G; Jiang Z; Li N; Zhang X
    Oncol Lett; 2019 Mar; 17(3):2960-2968. PubMed ID: 30854074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
    Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
    Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
    Jiang Y; Wang K; Lu X; Wang Y; Chen J
    Mol Immunol; 2021 Dec; 140():47-58. PubMed ID: 34653794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
    Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
    Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
    Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
    Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta.
    Siebert N; Zumpe M; Schwencke CH; Biskupski S; Troschke-Meurer S; Leopold J; Zikoridse A; Lode HN
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
    Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
    Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
    Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
    Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
    Zheng Q; Xu J; Gu X; Wu F; Deng J; Cai X; Wang G; Li G; Chen Z
    Am J Transl Res; 2020; 12(7):3212-3224. PubMed ID: 32774695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 20. CircSOD2 Contributes to Tumor Progression, Immune Evasion and Anti-PD-1 Resistance in Hepatocellular Carcinoma by Targeting miR-497-5p/ANXA11 Axis.
    Ye R; Lu X; Liu J; Duan Q; Xiao J; Duan X; Yue Z; Liu F
    Biochem Genet; 2023 Apr; 61(2):597-614. PubMed ID: 36008700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.